Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials.

Clin Transl Radiat Oncol · 2019 · PMC6357685 · PMID 30734002

Europe PMC DOI

hedged sentences

0.0588

closest p · 1.2× alpha

0.0588

boldest claim

The sentences

nearly reached significancep = 0.0588so close (0.05 < p ≤ 0.1)

However, for the MAESTRO trial, the hazard ratio of 0.84 nearly reached significance (p = 0.0588).

also in 125 other papers

approaching significanceno p-value reported

In the MAESTRO trial, where results were approaching significance, it would have been of great importance to have information regarding the hypoxic status of the tumors of each individual patient. 3 Improved hypoxia-activated prodrugs Each HAP candidate is a bespoke invention [42] , [43] , [62] .

also in 2,640 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.